Cell cycle-dependent DNA damage signaling induced by ICRF-193 involves ATM, ATR, CHK2, and BRCA1

Experimental Cell Research

Volumn 312, Issue 11, 2006, Pages 1996-2008

  Park, Iha ^a   Avraham, Hava Karsenty ^a  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Cell cycle; DNA damage; G2 arrest; ICRF 193; Topoisomerase II

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; CHECKPOINT KINASE 2; DNA TOPOISOMERASE (ATP HYDROLYSING); HISTONE H2AX; NIBRIN;

ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; DNA DAMAGE; FEMALE; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 33744923691     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.02.029     Document Type: Article

References (53)

1. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev., Mol. Cell Biol. 3 (2002) 430-440
2. Froelich-Ammon S.J., and Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270 (1995) 21429-21432
3. Andoh T., and Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta 1400 (1998) 155-171
4. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev., Cancer 3 (2003) 155-168
5. Alderton G.K., Joenje H., Varon R., Borglum A.D., Jeggo P.A., and O'Driscoll M. Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway. Hum. Mol. Genet. 13 (2004) 3127-3138
6. Brown E.J., and Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14 (2000) 397-402
7. Brown E.J., and Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev. 17 (2003) 615-628
8. Tibbetts R.S., Cortez D., Brumbaugh K.M., Scully R., Livingston D., Elledge S.J., and Abraham R.T. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev. 14 (2000) 2989-3002
9. Liu Q., Guntuku S., Cui X.S., Matsuoka S., Cortez D., Tamai K., Luo G., Carattini-Rivera S., Demayo F., Bradley A., Donehower L.A., and Elledge S.J. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14 (2000) 1448-1459
10. Ahn J.Y., Schwarz J.K., Piwnica-Worms H., and Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60 (2000) 5934-5936
11. Cortez D., Wang Y., Qin J., and Elledge S.J. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286 (1999) 1162-1166
12. Fernandez-Capetillo O., Chen H.T., Celeste A., Ward I., Romanienko P.J., Morales J.C., Naka K., Xia Z., Camerini-Otero R.D., Motoyama N., Carpenter P.B., Bonner W.M., Chen J., and Nussenzweig A. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat. Cell Biol. 4 (2002) 993-997
13. Lim D.S., Kim S.T., Xu B., Maser R.S., Lin J., Petrini J.H., and Kastan M.B. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404 (2000) 613-617
14. Lukas C., Melander F., Stucki M., Falck J., Bekker-Jensen S., Goldberg M., Lerenthal Y., Jackson S.P., Bartek J., and Lukas J. Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention. EMBO J. 23 (2004) 2674-2683
15. Mochan T.A., Venere M., Ditullio Jr. R.A., and Halazonetis T.D. 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res. 63 (2003) 8586-8591
16. Nakanishi K., Taniguchi T., Ranganathan V., New H.V., Moreau L.A., Stotsky M., Mathew C.G., Kastan M.B., Weaver D.T., and D'andrea A.D. Interaction of FANCD2 and NBS1 in the DNA damage response. Nat. Cell Biol. 4 (2002) 913-920
17. Stewart G.S., Wang B., Bignell C.R., Taylor A.M., and Elledge S.J. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421 (2003) 961-966
18. Wang B., Matsuoka S., Carpenter P.B., and Elledge S.J. 53BP1, a mediator of the DNA damage checkpoint. Science 298 (2002) 1435-1438
19. Stojic L., Mojas N., Cejka P., Di Pietro M., Ferrari S., Marra G., and Jiricny J. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev. 18 (2004) 1331-1344
20. Bolderson E., Scorah J., Helleday T., Smythe C., and Meuth M. ATM is required for the cellular response to thymidine induced replication fork stress. Hum. Mol. Genet. 13 (2004) 2937-2945
21. Ye R., Bodero A., Zhou B.B., Khanna K.K., Lavin M.F., and Lees-Miller S.P. The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner. J. Biol. Chem. 276 (2001) 4828-4833
22. Theard D., Coisy M., Ducommun B., Concannon P., and Darbon J.M. Etoposide and adriamycin but not genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR. Biochem. Biophys. Res. Commun. 289 (2001) 1199-1204
23. Tanabe K., Ikegami Y., Ishida R., and Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 51 (1991) 4903-4908
24. Iwai M., Hara A., Andoh T., and Ishida R. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells. FEBS Lett. 406 (1997) 267-270
25. Deming P.B., Cistulli C.A., Zhao H., Graves P.R., Piwnica-Worms H., Paules R.S., Downes C.S., and Kaufmann W.K. The human decatenation checkpoint. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 12044-12049
26. Pastor N., Dominguez I., Mateos S., and Cortes F. A comparative study of genotoxic effects of anti-topoisomerase II drugs ICRF-193 and bufalin in Chinese hamster ovary cells. Mutat. Res. 515 (2002) 171-180
27. Hajji N., Pastor N., Mateos S., Dominguez I., and Cortes F. DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193. Mutat. Res. 530 (2003) 35-46
28. Jensen L.H., Nitiss K.C., Rose A., Dong J., Zhou J., Hu T., Osheroff N., Jensen P.B., Sehested M., and Nitiss J.L. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines. J. Biol. Chem. 275 (2000) 2137-2146
29. Huang K.C., Gao H., Yamasaki E.F., Grabowski D.R., Liu S., Shen L.L., Chan K.K., Ganapathi R., and Snapka R.M. Topoisomerase II poisoning by ICRF-193. J. Biol. Chem. 276 (2001) 44488-44494
30. Boos G., and Stopper H. Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol. Lett. 116 (2000) 7-16
31. Mikhailov A., Shinohara M., and Rieder C.L. Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J. Cell Biol. 166 (2004) 517-526
32. Wood L.D., Halvorsen T.L., Dhar S., Baur J.A., Pandita R.K., Wright W.E., Hande M.P., Calaf G., Hei T.K., Levine F., Shay J.W., Wang J.J., and Pandita T.K. Characterization of ataxia telangiectasia fibroblasts with extended life-span through telomerase expression. Oncogene 20 (2001) 278-288
33. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., and Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273 (1998) 5858-5868
34. Fernandez-Capetillo O., Celeste A., and Nussenzweig A. Focusing on foci: H2AX and the recruitment of DNA-damage response factors. Cell Cycle 2 (2003) 426-427
35. Olive P.L., Banath J.P., and Durand R.E. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat. Res. 122 (1990) 86-94
36. Stiff T., O'driscoll M., Rief N., Iwabuchi K., Lobrich M., and Jeggo P.A. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 64 (2004) 2390-2396
37. Downes C.S., Clarke D.J., Mullinger A.M., Gimenez-Abian J.F., Creighton A.M., and Johnson R.T. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 372 (1994) 467-470
38. Hans F., and Dimitrov S. Histone H3 phosphorylation and cell division. Oncogene 20 (2001) 3021-3027
39. Pastor N., Jose Flores M., Dominguez I., Mateos S., and Cortes F. High yield of endoreduplication induced by ICRF-193: a topoisomerase II catalytic inhibitor. Mutat. Res. 516 (2002) 113-120
40. Akimitsu N., Kamura K., Tone S., Sakaguchi A., Kikuchi A., Hamamoto H., and Sekimizu K. Induction of apoptosis by depletion of DNA topoisomerase IIα in mammalian cells. Biochem. Biophys. Res. Commun. 307 (2003) 301-307
41. Woessner R.D., Mattern M.R., Mirabelli C.K., Johnson R.K., and Drake F.H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2 (1991) 209-214
42. Scully R., Chen J., Plug A., Xiao Y., Weaver D., Feunteun J., Ashley T., and Livingston D.M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88 (1997) 265-275
43. Rao P.N., and Hanks S.K. Chromatin structure during the prereplicative phases in the life cycle of mammalian cells. Cell Biophys. 2 (1980) 327-337
44. Hiraoka Y., Minden J.S., Swedlow J.R., Sedat J.W., and Agard D.A. Focal points for chromosome condensation and decondensation revealed by three-dimensional in vivo time-lapse microscopy. Nature 342 (1989) 293-296
45. Skoufias D.A., Lacroix F.B., Andreassen P.R., Wilson L., and Margolis R.L. Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. Mol. Cell 15 (2004) 977-990
46. Haggarty S.J., Koeller K.M., Kau T.R., Silver P.A., Roberge M., and Schreiber S.L. Small molecule modulation of the human chromatid decatenation checkpoint. Chem. Biol. 10 (2003) 1267-1279
47. Adachi N., Iiizumi S., So S., and Koyama H. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage. Biochem. Biophys. Res. Commun. 318 (2004) 856-861
48. Munoz P., Baus F., and Piette J. Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193. Oncogene 20 (2001) 1990-1999
49. Adachi N., Suzuki H., Iiizumi S., and Koyama H. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J. Biol. Chem. 278 (2003) 35897-35902
50. Munoz P., Zdzienicka M.Z., Blanchard J.M., and Piette J. Hypersensitivity of Ku-deficient cells toward the DNA topoisomerase II inhibitor ICRF-193 suggests a novel role for Ku antigen during the G2 and M phases of the cell cycle. Mol. Cell. Biol. 18 (1998) 5797-5808
51. Taylor W.R., and Stark G.R. Regulation of the G2/M transition by p53. Oncogene 20 (2001) 1803-1815
52. Kobayashi M., Adachi N., Aratani Y., Kikuchi A., and Koyama H. Decreased topoisomerase IIα expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells. Cancer Lett. 166 (2001) 71-77
53. Borde V., and Duguet M. DNA topoisomerase II sites in the histone H4 gene during the highly synchronous cell cycle of Physarum polycephalum. Nucleic Acids Res. 26 (1998) 2042-2049